BioSyent Releases Q4 And Full Year 2014 Results – Full Year Sales Up 57%; Pharma Sales Up 63%; Net Income Up 64%; Diluted Eps $0.22 Up 69%; Cash And Short-term Investments $8.0 Million Up 82%